company background image
ENTA

Enanta Pharmaceuticals NasdaqGS:ENTA Stock Report

Last Price

US$51.51

Market Cap

US$1.1b

7D

2.4%

1Y

-12.2%

Updated

27 Jan, 2023

Data

Company Financials +

Enanta Pharmaceuticals, Inc.

NasdaqGS:ENTA Stock Report

Mkt Cap: US$1.1b

ENTA Stock Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.

ENTA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 42.3% below our estimate of its fair value

Earnings are forecast to grow 63.66% per year

Risk Analysis

No risks detected for ENTA from our risk checks.

My Notes

New

Notes are coming soon

Enanta Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enanta Pharmaceuticals
Historical stock prices
Current Share PriceUS$51.51
52 Week HighUS$79.50
52 Week LowUS$37.59
Beta0.35
1 Month Change13.26%
3 Month Change8.67%
1 Year Change-12.25%
3 Year Change-0.058%
5 Year Change-40.98%
Change since IPO199.83%

Recent News & Updates

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Recent updates

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Oct 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04
Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Feb 11
Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Update: Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Gained 85% In The Last Five Years

Jan 23
Update: Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Gained 85% In The Last Five Years

Earnings Release: Here's Why Analysts Cut Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target To US$61.63

Nov 25
Earnings Release: Here's Why Analysts Cut Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target To US$61.63

Does Enanta Pharmaceuticals (NASDAQ:ENTA) Have A Healthy Balance Sheet?

Nov 24
Does Enanta Pharmaceuticals (NASDAQ:ENTA) Have A Healthy Balance Sheet?

Shareholder Returns

ENTAUS BiotechsUS Market
7D2.4%1.6%3.1%
1Y-12.2%10.5%-8.5%

Return vs Industry: ENTA underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: ENTA underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is ENTA's price volatile compared to industry and market?
ENTA volatility
ENTA Average Weekly Movement7.5%
Biotechs Industry Average Movement12.2%
Market Average Movement7.0%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: ENTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ENTA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995160Jay Lulyhttps://www.enanta.com

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Enanta Pharmaceuticals, Inc. Fundamentals Summary

How do Enanta Pharmaceuticals's earnings and revenue compare to its market cap?
ENTA fundamental statistics
Market CapUS$1.07b
Earnings (TTM)-US$121.75m
Revenue (TTM)US$86.16m

12.4x

P/S Ratio

-8.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENTA income statement (TTM)
RevenueUS$86.16m
Cost of RevenueUS$0
Gross ProfitUS$86.16m
Other ExpensesUS$207.92m
Earnings-US$121.75m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 07, 2023

Earnings per share (EPS)-5.85
Gross Margin100.00%
Net Profit Margin-141.31%
Debt/Equity Ratio0.4%

How did ENTA perform over the long term?

See historical performance and comparison